Cancer, Gender Dysphoria Patients Gain Vital Drug Access

The Pharmaceutical Benefits Advisory Committee has advised the federal government to fund triptorelin for widespread use, including treatments for breast cancer, endometriosis, and gender dysphoria. This recommendation stems from AstraZeneca's decision to withdraw Zoladex from the market, potentially leaving over 7,500 women with breast cancer without a treatment option. Triptorelin, already PBS-listed for prostate cancer since 2006, functions by blocking oestrogen and testosterone release, essential for some cancer treatments and fertility preservation.

The expanded Pharmaceutical Benefits Scheme (PBS) listing is projected to take effect in November. This move is considered a significant step forward for breast cancer patients, with access to the drug potentially being a matter of life and death. For endometriosis and pelvic pain patients, it offers a crucial alternative, although further research on its exact efficacy compared to Zoladex is noted.

Furthermore, the decision marks the first time gender-affirming care will be funded by the federal taxpayer through the PBS. This will remove a substantial financial barrier for transgender children in Queensland and the Northern Territory. The cost of private prescriptions could decrease from approximately $3,000 annually to $300, making essential treatments more accessible despite recent state government bans in Queensland and the Northern Territory.